Calidi Biotherapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Calidi Biotherapeutics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Shareholder Slice Ratio: Share count rose 2,312% in 3 years, so each share's slice of the company became smaller. Bigger rise in share count than 93% of Healthcare companies in United States.
- Cash Cushion Ratio: Cash, after subtracting all debt, is 1.3 times its market value (net cash). Higher than 91% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
-94.3×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 81% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 2/3Sales grew in 0 of the last 3 years; profit grew in 2 of 3.
Less steady than 70% of Healthcare companies in United States.
Growth Efficiency Ratio
—Sales fell 100%
Sales fell 100% in 3 years, so extra profit per extra sales cannot be measured.
Asset Productivity Ratio
-100% / +241%In 3 years sales changed by -100% while total assets changed by +241%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
-14.0×Operating cash was negative last year, while some debt falls due within a year.
Higher than 51% of Healthcare companies in United States.
Cash Cushion Ratio
1.3× cashCash, after subtracting all debt, is 1.3 times its market value (net cash).
Higher than 91% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (11)
Calidi Biotherapeutics, Inc. made a loss over the last year. Calidi Biotherapeutics, Inc. owes $0.57 for every $1 it owns. Calidi Biotherapeutics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossCalidi Biotherapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
0.76The share price is 0.76 times Calidi Biotherapeutics, Inc.'s book value per share, lower than 85% of Healthcare companies in United States.
Market cap
$2 MThe total market value of all of Calidi Biotherapeutics, Inc.'s shares at today's price (share price × number of shares), smaller than 97% of Healthcare companies in United States. PosiCap size class: Nano Cap.
Net worth (book value)
$3 MWhat Calidi Biotherapeutics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$0.85Net worth divided by the number of shares. The share price of $0.65 is 0.8 times this, which is the P/B above.
Return on equity (ROE)
-672.2%Calidi Biotherapeutics, Inc. lost 672.2% of its shareholders' money over the last year, lower than 95% of Healthcare companies in United States.
Owes vs Owns
0.57×Calidi Biotherapeutics, Inc. owes $0.57 for every $1 it owns (moderate), higher than 61% of Healthcare companies in United States.
Dividend yield
NoneCalidi Biotherapeutics, Inc. does not currently pay a dividend.
Profit growth
LossCalidi Biotherapeutics, Inc. made a loss in each of the last two years.
Interest cover
Not coveredCalidi Biotherapeutics, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashCalidi Biotherapeutics, Inc. held $3 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Calidi Biotherapeutics, Inc.: $2 M ÷ $3 M (30 Jun 2026) = 0.8.
What is Calidi Biotherapeutics, Inc.'s return on equity?
Calidi Biotherapeutics, Inc. lost 672.2% of its shareholders' money over the last year, lower than 95% of Healthcare companies in United States.
How much does Calidi Biotherapeutics, Inc. owe compared with what it owns?
Calidi Biotherapeutics, Inc. owes $0.57 for every $1 it owns (moderate), higher than 61% of Healthcare companies in United States.
Does Calidi Biotherapeutics, Inc. pay a dividend?
No. Calidi Biotherapeutics, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.